RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Stoke Therapeutics Stock

Stoke Therapeutics Revenue 2024

Stoke Therapeutics Revenue

15.63 M USD

Ticker

STOK

ISIN

US86150R1077

WKN

A2PLTL

In 2024, Stoke Therapeutics's sales reached 15.63 M USD, a 78.03% difference from the 8.78 M USD sales recorded in the previous year.

The Stoke Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e278.59-
2028e163.01-
2027e69.41-
2026e29.06-
2025e17.54-
2024e15.63-
20238.78-
202212.41-
2021--
2020--
2019--
2018--
2017--

Stoke Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Stoke Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Stoke Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Stoke Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Stoke Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Stoke Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Stoke Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Stoke Therapeutics’s growth potential.

Stoke Therapeutics Revenue, EBIT and net profit per share

DateStoke Therapeutics RevenueStoke Therapeutics EBITStoke Therapeutics Net Income
2029e278.59 M undefined0 undefined35.44 M undefined
2028e163.01 M undefined-93.8 M undefined-43.18 M undefined
2027e69.41 M undefined-133.91 M undefined-90.44 M undefined
2026e29.06 M undefined-167.4 M undefined-125.67 M undefined
2025e17.54 M undefined-154.08 M undefined-133.69 M undefined
2024e15.63 M undefined-128.05 M undefined-114.3 M undefined
20238.78 M undefined-114.77 M undefined-104.7 M undefined
202212.41 M undefined-104.36 M undefined-101.07 M undefined
20210 undefined-86.07 M undefined-85.81 M undefined
20200 undefined-53.04 M undefined-52.24 M undefined
20190 undefined-35.68 M undefined-32.33 M undefined
20180 undefined-12.78 M undefined-12.52 M undefined
20170 undefined-5.55 M undefined-5.56 M undefined

Stoke Therapeutics stock margins

The Stoke Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Stoke Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Stoke Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Stoke Therapeutics's sales revenue. A higher gross margin percentage indicates that the Stoke Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Stoke Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Stoke Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Stoke Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Stoke Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Stoke Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Stoke Therapeutics Margin History

Stoke Therapeutics Gross marginStoke Therapeutics Profit marginStoke Therapeutics EBIT marginStoke Therapeutics Profit margin
2029e0 %0 %12.72 %
2028e0 %-57.54 %-26.49 %
2027e0 %-192.93 %-130.3 %
2026e0 %-576.04 %-432.43 %
2025e0 %-878.34 %-762.13 %
2024e0 %-819.22 %-731.24 %
20230 %-1,307.21 %-1,192.47 %
20220 %-840.93 %-814.42 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Stoke Therapeutics Aktienanalyse

What does Stoke Therapeutics do?

Stoke Therapeutics Inc is a biopharmaceutical company founded in 2018 by experienced scientists to develop innovative therapeutic approaches for rare genetic diseases. The company's headquarters is located in Bedford, Massachusetts, and since its inception, it has continuously invested to expand its business and its development process. In 2019, the company announced a financing round of $90 million to advance the development of its pipeline and clinical trials. Stoke Therapeutics specializes in the development of therapeutics for the treatment of rare genetic diseases caused by mutations in haploinsufficiency genes. These diseases are caused by mutations in one of the two genes that code for a specific protein. Since a single defective gene is not sufficient to maintain the normal functions of a protein, serious health problems arise. Stoke's therapeutics aim to replace the missing gene product by targeted stimulation of the healthy gene. This is achieved through the development of antisense oligonucleotide-based therapeutics. Antisense oligonucleotides are small DNA-like molecules that are able to address, recognize, and bind to specific genes. By binding to the healthy gene, they can promote its expression and thereby replace the missing protein. The company's pipeline currently includes a range of products at various stages of development, including preclinical and clinical trials. The following products are the most important: STK-001: A product developed for the treatment of severe forms of Dravet syndrome. Dravet syndrome is a rare genetic disease characterized by seizures, developmental delays, and other neurological symptoms. STK-002: A product for the treatment of haploinsufficiency in STING1-associated vasculopathic syndrome (SAVS). SAVS is a rare genetic disease characterized by cardiovascular disorders and increased susceptibility to infections. STK-005: A product for the treatment of haploinsufficiency in adrenoleukodystrophy (ALD). ALD is a rare disease characterized by inflammatory and degenerative changes in the nervous system. Due to its innovative technology and focus on rare genetic diseases, Stoke Therapeutics has attracted the attention of many investors and potential partners. In 2020, the company entered into collaboration agreements with Roche Holdings and Ribometrix Inc to accelerate the development and commercialization of its therapeutics. Overall, Stoke Therapeutics has a promising future as it is able to provide a much-needed treatment option for patients with rare genetic diseases who currently have no effective therapies available. Stoke Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Stoke Therapeutics's Sales Figures

The sales figures of Stoke Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Stoke Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Stoke Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Stoke Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Stoke Therapeutics stock

How much revenue did Stoke Therapeutics generate this year?

Stoke Therapeutics has achieved a revenue of 15.63 M USD this year.

How much was the turnover of the company Stoke Therapeutics compared to the previous year?

The revenue of Stoke Therapeutics has increased by 78.03% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Stoke Therapeutics?

The revenue of Stoke Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Stoke Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Stoke Therapeutics so important for investors?

The revenue of Stoke Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Stoke Therapeutics pay?

Over the past 12 months, Stoke Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Stoke Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Stoke Therapeutics?

The current dividend yield of Stoke Therapeutics is .

When does Stoke Therapeutics pay dividends?

Stoke Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Stoke Therapeutics?

Stoke Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Stoke Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Stoke Therapeutics located?

Stoke Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Stoke Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Stoke Therapeutics from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Stoke Therapeutics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Stoke Therapeutics in the year 2023?

In the year 2023, Stoke Therapeutics distributed 0 USD as dividends.

In which currency does Stoke Therapeutics pay out the dividend?

The dividends of Stoke Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Stoke Therapeutics

Our stock analysis for Stoke Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stoke Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.